Tandem Autologous Transplantation Can Overcome the Poor Prognosis of Double-Hit Multiple Myeloma Patients With 1q21 Gain/Amp and t(4;14)

被引：0

作者：

Huang, Beihui ^{[1
]}

Li, Juan ^{[1
]}

Wang, Xiuju ^{[2
]}

Huang, Hongming ^{[3
]}

Xu, Xiaojun ^{[4
]}

Wu, Bingyi ^{[5
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China

[3] Nantong Univ, Affiliated Hosp, Nantong, Peoples R China

[4] Sun Yat Sen Univ, Affiliated Hosp 7, Guangzhou, Guangdong, Peoples R China

[5] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-339

引用

页码：S229 / S229

页数：1

共 50 条

[1] Poor prognosis associated with gain of chromosome 1Q21 in multiple myeloma may be overcome by treatment with a bortezomib combination
Sagaster, V.
Odelga, V.
Kaufmann, H.
Ackermann, J.
Galhuber, M.
Zojer, N.
Ludwig, H.
Wieser, R.
Zielinski, C.
Drach, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 149 - 149
[2] The Role of 1q21 Gain on the Prognosis of Multiple Myeloma
Dong Hui Xing
Jin Huan Wang
Zhi Gang Zhao
Journal of Nutritional Oncology, 2021, 6 (02) : 50 - 56
[3] Impact of Gain 1q21 (1q21+) in Patients with multiple Myeloma and Translocation t(11;14)
Udovica, S.
Scherbler, W.
Fritz, P.
Schneller, A.
Ludwig, H.
Zojer, N.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 144 - 144
[4] Concomitant 1q+and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
Ozga, Michael
Zhao, Qiuhong
Huric, Laila
Miller, Cecelia
Rosko, Ashley
Khan, Abdullah
Umyarova, Elvira
Benson, Don
Cottini, Francesca
BLOOD CANCER JOURNAL, 2023, 13 (01)
[5] Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
Michael Ozga
Qiuhong Zhao
Laila Huric
Cecelia Miller
Ashley Rosko
Abdullah Khan
Elvira Umyarova
Don Benson
Francesca Cottini
Blood Cancer Journal, 13
[6] 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib
Du, Chenxing
Mao, Xuehan
Xu, Yan
Yan, Yuting
Yuan, Chenglu
Du, Xin
Liu, Jiahui
Fan, Huishou
Wang, Qi
Sui, Weiwei
Deng, Shuhui
Fu, Mingwei
Li, Zengjun
Li, Chengwen
Zhao, Jiawei
Yi, Shuhua
Liu, Lanting
Hao, Mu
Zou, Dehui
Zhao, Yaozhong
Qiu, Lugui
An, Gang
LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1201 - 1210
[7] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
Yuanyuan Jin
Xiaochen Yu
Jianhua Du
Hui Li
Wenjiao Tang
Congwei Jia
Yunyan Zan
Miao Chen
Yanbin Zhang
Minhong Yu
Weiqi Rong
Daobin Zhou
Junling Zhuang
Annals of Hematology, 2021, 100 : 1251 - 1260
[8] 1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma
Du, Chenxing
Gang, An
Xu, Yan
Mao, Xuehan
Yan, Yuting
Liu, Jiahui
Fan, Huishou
Sui, Weiwei
Deng, Shuhui
Li Zengjun
Li, Chengwen
Yi, Shuhua
Hao, Mu
Zou, Dehui
Zhan, Fenghuang
Tai, Yu-Tzu
Anderson, Kenneth C.
Qiu, Lugui
BLOOD, 2019, 134
[9] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
Jin, Yuanyuan
Yu, Xiaochen
Du, Jianhua
Li, Hui
Tang, Wenjiao
Jia, Congwei
Zan, Yunyan
Chen, Miao
Zhang, Yanbin
Yu, Minhong
Rong, Weiqi
Zhou, Daobin
Zhuang, Junling
ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1251 - 1260
[10] THE POOR PROGNOSIS ASSOCIATED WITH GAIN/AMPLIFICATION OF 1Q21 IN RELAPSED MULTIPLE MYELOMA PATIENTS MAY BE OVERCOME BY VELCADE BASED REGIMEN IN CONTRARY OF THALIDOMIDE BASED REGIMEN
Nemec, P.
Greslikova, H.
Smetana, J.
Zaoralova, R.
Kupska, R.
Berankova, K.
Filkova, H.
Kralova, D.
Krejci, M.
Pour, L.
Zahradova, L.
Sandecka, V.
Adam, Z.
Kuglik, P.
Hajek, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 227 - 228

← 1 2 3 4 5 →